SENSCIS
- Health
New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1
Ingelheim, Germany: Interim analysis demonstrated long-term safety and suggested a sustained effect of nintedanib on slowing lung function decline in…
Read More »